Health in Belgium 1,279 indicators covering health for Belgium. IndicatorLatest Year10-yr change Rank People having a long-standing illness or health problem, by sex, age 8.5 2025 down 6.6% 27th Children with a birth weight 99.4 2019 down 0.6% 20th Healthy life years by sex 82.4 2024 up 1.2% 13th New cases: other 0 2012 — 33rd Compliance with international health regulations 82 2016 up 10.8% 61st Health care expenditure by function 68,655 2024 up 59.7% 9th Health care expenditure by financing scheme 68,655 2024 up 59.7% 9th Expenditure for selected health care functions by health care 68,655 2024 up 59.7% 9th Health care expenditure by provider 68,655 2024 up 59.7% 8th Expenditure for selected health care providers by health care 68,655 2024 up 59.7% 8th Expenditure for selected health care functions by health care 68,655 2024 up 59.7% 8th Persons having a longstanding health problem by level of disability 8.5 2025 down 6.6% 27th Self-perceived health by level of disability (activity limitation) 93.6 2025 unchanged 16th Healthy life expectancy based on self-perceived health 76.6 2024 up 2.4% 14th Deaths and disappearances during migration 1 2024 unchanged 59th 1.1.1 Children living in households in extreme poverty 0.0837 2022 down 27.6% 47th Infant mortality by age and sex 106 2024 down 7.8% 15th Number of imported cases of cutaneous leishmaniasis reported 33 2023 up 175.0% 7th Number of imported cases of visceral leishmaniasis reported 3 2023 up 200.0% 11th Health impacts of air pollution 30,396 2023 down 66.9% 16th Technical resources in hospital 1,483 2024 up 16.4% 7th Primary health care expenditure (PHCE) per сapita in US$ 2,067 2023 up 22.3% 14th Revenues of health care financing schemes 68,655 2024 up 59.7% 6th Revenues of health care financing schemes by health care financing 68,655 2024 up 59.7% 6th Deaths related to infectious diseases 1,584 2023 up 8.2% 11th Causes of death - infant mortality by country of occurrence 331 2023 down 25.8% 10th Fetal, peri- and neonatal mortality rates by country of occurrence 5.9 2023 up 20.4% 6th Peri-neonatal mortality by age of mother, country of residence and 654 2023 up 6.5% 7th Reported cases of gonorrhea 6,622 2023 up 555.0% 9th Reported cases of syphilis 2,545 2023 up 193.5% 8th Causes of death - potential years of life lost by treatable and 2,683 2023 down 23.0% 22nd People having a long-standing illness or health problem, by sex, age 27.1 2025 up 17.3% 9th Treatable and preventable mortality of residents by cause and sex 20,920 2023 down 10.0% 15th Antimicrobial resistance or decreased susceptibiity (DS/R) to 43 2022 up 2,199.5% 3rd Antimicrobial resistance or decreased susceptibiity (DS/R) to 200 2022 up 86.9% 20th Causes of death - infant mortality by country of residence 319 2023 down 26.7% 9th Influenza vaccination rate elderly oecd 59.1 2018 down 9.1% 21st Reported cases of chlamydia 10,179 2023 up 104.3% 14th Excess mortality by month -11.7 2026 down 161.9% 27th Breast cancer screening coverage in europe 56.9 2022 down 9.3% 12th Consumption of antibiotics in the community and hospital sectors 20.6 2024 down 14.2% 14th Total use of antibacterials expressed as DDD per 1000 inhabitants per 20.93 2023 down 13.9% 20th Pattern of antibiotic consumption at national level 69.04 2023 up 9.8% 19th Hospital days of in-patients - historical data 10.04 million 2021 down 21.1% 12th Hospital discharges by diagnosis, in-patients, total number 1.75 million 2021 down 6.5% 9th Hospital discharges by diagnosis, in-patients, per 100 000 15,113 2021 down 10.9% 9th Cancer screening rates in europe 54.76 2022 down 7.8% 11th Cervical cancer screening coverage in europe 54.76 2022 down 7.8% 11th Infant mortality by mother's educational attainment level (ISCED11f) 378 2024 down 10.6% 8th Imports in 1000s hectolitres 1.17 2007 down 99.9% 128th Hospital discharges by diagnosis, day cases, total number 2.07 million 2021 up 23.6% 6th Number of isolates tested for ceftriaxone 159 2020 up 44.5% 20th Proportion of isolates with decreased susceptibility or resistance 0.6 2020 — 10th Hospital discharges by diagnosis, day cases, per 100 000 inhabitants 17,887 2021 up 17.9% 3rd Proportion of isolates with resistance to azithromycin reported to 17.6 2020 up 545.3% 7th Number of isolates tested for azithromycin 159 2020 up 44.5% 21st Households with out-of-pocket payments greater than 40% of capacity 5.2% 2020 up 9.7% 17th Proportion of isolates with resistance to ciprofloxacin reported to 44.4 2018 down 34.0% 40th Number of isolates tested for ciprofloxacin 180 2018 up 63.6% 23rd 4.1.1 Proportion of children and young people at the end of lower 80.34 2018 down 0.8% 17th ← Previous Page 21 of 22 Next →